BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, April 14, 2026
Home » Topics » Inflammatory, BioWorld

Inflammatory, BioWorld
Inflammatory, BioWorld RSS Feed RSS

Tinted Euro symbol
Newco news

Enodia jumps ahead in Sec61 targeting, adds Kezar’s program

March 16, 2026
By Brian Orelli
No Comments
Enodia Therapeutics Inc. was spun out of The Institut Pasteur by Argobio Studio based on the work of Caroline Demangel, co-founder of Enodia and head of the immunobiology and therapy unit at The Institut Pasteur. Demangel’s lab discovered the mechanism of action of mycolactone, a natural Sec61 inhibitor that causes Buruli ulcers.
Read More
Illustration of inflamed spine

China’s Qyuns moves IL-17 biologic toward first approval

March 11, 2026
By Tamra Sami
No Comments
Qyuns Therapeutics Co. Ltd. has moved closer to its first commercial product after China’s National Medical Products Administration (NMPA) accepted its NDA for IL-17 antibody crusekitug (QX-002N) for treating ankylosing spondylitis (AS), a chronic inflammatory disease that affects the spine and sacroiliac joints.
Read More
Illustration of siRNA structure

GSK nabs two Frontier Biotech siRNA assets in $1B deal

Feb. 25, 2026
By Marian (YoonJee) Chu
No Comments
GSK plc will pay Frontier Biotechnologies Inc. $40 million up front and up to $963 million in milestone payments to license two of Frontier’s small interfering RNA-based assets in the field of immunology.
Read More
Illustration of human anatomy showing lymphatic system
Endocrine/metabolic

Targeting cholesterol deposition could treat lymphedema

Feb. 11, 2026
By Mar de Miguel
No Comments
The malfunction of lymphatic drainage that occurs in lymphedema leads to excessive cholesterol accumulation in the affected skin and lymphatic vessels, causing inflammation and fibrosis. However, surgery and the chemical reduction of accumulated cholesterol with cyclodextrin reduce inflammation and regenerate lymphatic vessels. Cholesterol is a potential therapeutic target for treating lymphedema, according to this study published on Feb. 11, 2026, in Nature by Veronique Angeli and her colleagues.
Read More

Iambic raises the bard in AI, pens $1.7B Takeda deal

Feb. 9, 2026
By Randy Osborne
No Comments
Iambic Therapeutics Inc.’s multiyear technology and discovery pact with Takeda Pharmaceutical Co. Ltd. could help the San Diego-based firm advance its own pipeline in a big way.
Read More

Priovant’s brepo impresses in phase II cutaneous sarcoidosis trial

Feb. 6, 2026
By Jennifer Boggs
No Comments
On the heels of an NDA submission for brepocitinib in dermatomyositis, Priovant Therapeutics Inc. disclosed data showing the dual TYK2/JAK1 inhibitor surpassed expectations in a phase II study in cutaneous sarcoidosis, another chronic inflammatory skin condition with limited treatment options, setting the stage for a phase III study set to start this year.
Read More
Art concept for mouse model

A humanized mouse mimics Fcγ receptor biology in antibody assays

Feb. 6, 2026
By Mar de Miguel
No Comments
Scientists at Ghent University have created a mouse model that incorporates human versions of the receptors that recognize the fragment crystallizable region of immunoglobulin G, one of the most abundant antibodies in the blood and a key mediator of essential immune functions such as cellular activation, pathogen elimination and the regulation of inflammatory responses.
Read More
Amgen headquarters

Amgen thumbs-down on FDA’s ask, Tavneos sales continue

Feb. 4, 2026
By Randy Osborne
No Comments
Amgen Inc.’s head of R&D James Bradner said his firm was “surprised” by the request from the U.S. FDA Jan. 16 to take Tavneos (avacopan) off the market – and the company said no. “We're in discussions with FDA, and we'll answer questions as we talk with them,” he added.
Read More
Lungs

Study digs into links between age, sex, hormones and asthma

Jan. 28, 2026
By Anette Breindl
No Comments
The prevalence of asthma differs between men and women, and furthermore, the difference changes over the lifespan. “Asthma is more common in boys than girls, but more common in women than men,” Clare Lloyd told BioWorld. Females are particularly susceptible to asthma during developmental periods of hormonal changes, also known as puberty, pregnancy and menopause.
Read More
Sinus anatomy with virus cells
Respiratory

The nose could be the key to common-cold immunity

Jan. 20, 2026
By Mar de Miguel
No Comments
The range of effects caused by rhinoviruses – the pathogens responsible for the common cold – motivated scientists at Yale University to study the human nasal epithelium and uncover a previously undescribed defense mechanism. The interferon-mediated protective response in these cells can limit infection, whereas a maladaptive response tends to worsen it. Based on these findings, the researchers have identified potential therapeutic targets to reduce inflammation associated with rhinovirus infection.
Read More
Previous 1 2 3 4 5 6 7 8 9 … 24 25 Next

Popular Stories

  • Today's news in brief

    BioWorld
  • MMP inhibitors divulged in Accure Therapeutics patent

    BioWorld Science
    Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for April 7, 2026
  • MSD discloses new HCN1/2 blockers

    BioWorld Science
    Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
  • Cancer cell in the cross-hairs

    Selective CBL-B inhibitor with improved safety profile disclosed

    BioWorld Science
    CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing